Search

Your search keyword '"Kyrtsonis, Marie‐Christine"' showing total 40 results
Start Over Author "Kyrtsonis, Marie‐Christine" Topic health sciences
40 results on '"Kyrtsonis, Marie‐Christine"'

2. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP

Author

Vassilakopoulos, Theodoros P. Michail, Michail Papageorgiou, Sotirios Kourti, Georgia Angelopoulou, Maria K. Panitsas, Fotios Sachanas, Sotirios Kalpadakis, Christina Katodritou, Eirini Leonidopoulou, Theoni Kotsianidis, Ioannis and Hatzimichael, Eleftheria Kotsopoulou, Maria Dimou, Maria and Variamis, Eleni Boutsis, Dimitrios Terpos, Evangelos and Dimopoulou, Maria N. Karakatsanis, Stamatios Michalis, Eurydiki and Karianakis, George Tsirkinidis, Pantelis Vadikolia, Chryssa and Poziopoulos, Christos Pigaditou, Anna Vrakidou, Effimia and Economopoulos, Theophanis Kyriazopoulou, Lydia Siakantaris, Marina P. Kyrtsonis, Marie-Christine Symeonidis, Argyris and Anargyrou, Konstantinos Papaioannou, Maria Hatjiharissi, Evdoxia and Vervessou, Elissavet Tsirogianni, Maria Palassopoulou, Maria and Gainaru, Gabriella Stefanoudaki, Ekaterini Zikos, Panayiotis and Tsirigotis, Panayiotis Tsourouflis, Gerasimos and Assimakopoulou, Theodora Konstantinidou, Pavlina Papadaki, Helen A. Megalakaki, Katerina Dimopoulos, Meletios-Athanasios and Pappa, Vassiliki Karmiris, Themis Roussou, Paraskevi and Panayiotidis, Panayiotis Konstantopoulos, Kostas Pangalis, Gerassimos A.

Subjects
hemic and lymphatic diseases, Health Sciences, Επιστήμες Υγείας
Abstract

Background R-CHOP can cure approximately 75% of patients with primary mediastinal large B-cell lymphoma (PMLBCL), but prognostic factors have not been sufficiently evaluated yet. R-da- EPOCH is potentially more effective but also more toxic than R-CHOP. Reliable prognostic classification is needed to guide treatment decisions. Materials and Methods We analyzed the impact of clinical prognostic factors on the outcome of 332 PMLBCL patients = 2 times upper limit of normal (model A) were significantly associated with FFP; E/IV and bulky disease (model B) were associated with LSS. Both models performed better than the International Prognostic Index (IPI) and the age-adjusted IPI by Harrel’s C rank parameter and Akaike information criterion. Both models A and B defined high-risk subgroups (13%-27% of patients [pts]) with approximately 19%-23% lymphoma-related mortality. They also defined subgroups composing approximately one-fourth or one-half of the patients, with 11% risk of failure and only 1% or 4% 5-year lymphoma-related mortality. Conclusion The combination of E/IV with either bulky disease or LDH >= 2 times upper limit of normal defined high-risk but not very-high-risk subgroups. More importantly, their absence defined subgroups comprising approximately one-fourth or one-half of the pts, with 11% risk of failure and minimal lymphoma-related mortality, who may not need more intensive treatment such as R-da-EPOCH. Implications for Practice By analyzing the impact of baseline clinical characteristics on outcomes of a large cohort of patients with primary mediastinal large B-cell lymphoma homogeneously treated with R-CHOP with or without radiotherapy, we developed novel prognostic indices which can aid in deciding which patients can be adequately treated with R-CHOP and do not need more intensive regimens such as R-da-EPOCH. The new indices consist of objectively determined characteristics (extranodal disease or stage IV, bulky disease, and markedly elevated serum lactate dehydrogenase), which are readily available from standard initial staging procedures and offer better discrimination compared with established risk scores (International Prognostic Index [IPI] and age-adjusted IPI).

Published
2021

5. Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group

Author

Gavriatopoulou, Maria Kastritis, Efstathios and Ntanasis-Stathopoulos, Ioannis Kyrtsonis, Marie-Christine and Symeonidis, Argiris Hatjiharissi, Evdoxia Repousis, Panagiotis and Giannakoulas, Nikolaos Spanoudakis, Emmanouil G. Delibasi, Sossana Michali, Evridiki Michael, Michalis D. Vassou, Amalia Giannouli, Stavroula Iskas, Michail Kaiafa, Georgia and Tsirigotis, Panagiotis Pouli, Anastasia Vervessou, Elina and Christoulas, Dimitrios Katodritou, Eirini Terpos, Evangelos and Dimopoulos, Meletios A.

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2018

9. A Revised Staging System for Waldenström’s Macroglobulinemia

Author

Gavriatopoulou, Maria Kastritis, Efstathios Kyrtsonis, Marie Christine Hatjiharissi, Evdoxia Katodritou, Eirini Repousis, Panagiotis Symeonidis, Argiris Michael, Michalis Pouli, Anastasia Giannakoulas, Nikolaos others

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2017

10. Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents

Author

Katodritou, Eirini Terpos, Evangelos Delimpasi, Sossana and Kotsopoulou, Maria Michalis, Eurydiki Vadikolia, Chrysanthi and Kyrtsonis, Marie-Christine Symeonidis, Argiris Giannakoulas, Nikolaos Vadikolia, Chrissa Michael, Michalis Kalpadakis, Christina Gougopoulou, Theodora Prokopiou, Chrystalla and Kaiafa, Georgia D. Christoulas, Dimitrios Gavriatopoulou, Maria and Giannopoulou, Evlampia Lampropoulou, Vasiliki Verrou, Evgenia Kastritis, Efstathios Konstantinidou, Pavlina and Anagnostopoulos, Achilles Dimopoulos, Meletios A.

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2016

19. The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group

Author

Terpos, Evangelos Christoulas, Dimitrios Kastritis, Efstathios Katodritou, Eirini Papatheodorou, Athanasios Pouli, Anastasia Kyrtsonis, Marie-Christine Michalis, Eurydiki Papanikolaou, Xenophon Gkotzamanidou, Maria others

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2014

22. Prognostication of the High-Risk WM Patient

Author

Kastritis, Efstathios Gavriatopoulou, Maria Kyrtsonis, Marie-Christine Michael, Michael Hadjiharissi, Evdoxia Symeonidis, Argiris Michalis, Eurydiki Repoussis, Panagiotis Tsatalas, Konstantinos Sioni, Anastasia others

Subjects
Health Sciences, Επιστήμες Υγείας
Abstract

Waldenstrom’s macroglobulinemia is characterized by a protracted course in most patients and the median survival may be long. However, a subset of patients may present with more aggressive disease that is associated with short survival. In order to better characterize these “poor-risk” patients, we identified patients who died within 2 years from the initiation of front-line treatment. These patients were older and had more often features of aggressive disease, such as elevated LDH and low serum albumin than the standard-risk population. Furthermore, only a minority of poor-risk patient had a response to initial therapy. However, conventional clinical factors or even the lack on response could not adequately identify poor-risk patients, indicating the need for novel molecular or other markers that would be able to effectively recognize patients at greatest need for aggressive therapies.

Published
2011

26. Clinical Characteristics and Outcome of Primary Systemic Light-Chain Amyloidosis in Greece

Author

Michael, Michael Kastritis, Efstathios Delimpassi, Sossana Michalis, Evridiki Repoussis, Panagiotis Kyrtsonis, Marie-Christine Katodritou, Eirini Anagnostopoulos, Nicolaos Zervas, Konstantinos Dimopoulos, Meletios A

Subjects
Health Sciences, Επιστήμες Υγείας
Abstract

Background: Primary systemic light-chain (AL) amyloidosis is characterized by the deposition of immunoglobulin light chain-derived amyloid fibrils in various tissues leading to multiorgan dysfunction. Patients and Methods: In order to define characteristics, treatment, and outcome of Greek patients with AL amyloidosis, we analyzed 112 unselected patients with AL from several hospitals. Results: The heart was involved in 59% of patients and kidneys in 71%. Patients were treated with several different treatment regimens; high-dose dexamethasone-based regimens were used as primary treatment in 43% and melphalan-based regimens in 37%, while 12% received up-front bortezomib with dexamethasone. A hematologic response to first-line therapy was documented in 50% (complete response, 14.5%), and organ responses were observed in 25% of patients, the latter being strongly associated with achievement of hematologic response. Median overall survival was 34.2 months and was independently affected by heart involvement, creatinine, age, involvement of >= 2 organs, and bone marrow plasmacytosis > 30%. In patients with cardiac involvement, advanced age and extended bone marrow plasmacytosis were associated with an even worse outcome, while for patients without heart involvement, only bone marrow plasmacytosis was independently associated with survival. Hematologic response was associated with improved survival in patients with heart involvement but mostly in patients with less bone marrow infiltration. Conclusion: In this first series of patients from Greece with AL amyloidosis, disease features and outcome appeared similar to those reported from tertiary centers. Heart involvement and bone marrow plasma cell infiltration comprise adverse prognostic factors but also indicate the heterogeneity of the disease and the need for individual treatment approaches.

Published
2010

27. Seminars in

Author

Dimopoulos, Meletios A Attal, Michel Kyrtsonis, Marie-Christine Maltezas, Dimitrios Tzenou, Tatiana Koulieris, Efstathios Bradwell, Arthur R Rajkumar, S Vincent Sonneveld, Pieter Harousseau, Jean-Luc others

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2009

29. Seminars in

Author

Dimopoulos, Meletios A Attal, Michel Kyrtsonis, Marie-Christine Maltezas, Dimitrios Tzenou, Tatiana Koulieris, Efstathios Bradwell, Arthur R Rajkumar, S Vincent Sonneveld, Pieter Harousseau, Jean-Luc others

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2009

35. Clinical Characteristics and Outcome of Primary AL Amyloidosis in Greece

Author

Michail, Michalis Kastritis, Efstathios Delimpassi, Sossana Kyrtsonis, Marie Christine Michali, Evridiki Anagnostopoulos, Nicolaos Zervas, Konstantinos Katodritou, Eirini Panagiotidis, Panagiotis Tzenou, Natalia others

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2007

36. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide

Author

Dimopoulos, Meletios Athanasios Anagnostopoulos, Athanasios and Kyrtsonis, Marie-Christine Zervas, Konstantinos Tsatalas, Constantinos Kokkinis, Garyfallia Repoussis, Panagiotis and Symeonidis, Argyris Delimpasi, Souzana Katodritou, Eirini and Vervessou, Elina Michali, Evridiki Pouli, Anastasia Gika, Dimitra Vassou, Amalia Terpos, Evangelos Anagnostopoulos, Nikolaos Economopoulos, Theophanis Pangalis, Gerasimos

Subjects
Health Sciences, Επιστήμες Υγείας
Abstract

Purpose Alkylating agents and the anti-CD20 monoclonal antibody rituximab are among appropriate choices for the primary treatment of symptomatic patients with Waldenstrom macroglobulinemia ( WM), and they induce at least a partial response in 30% to 50% of patients. To improve these results, we designed a phase II study that included previously untreated symptomatic patients with WM who received a combination of dexamethasone, rituximab, and cyclophosphamide ( DRC). Patients and Methods Seventy-two patients were treated with dexamethasone 20 mg intravenously followed by rituximab 375 mg/ m(2) intravenously on day 1 and cyclophosphamide 100 mg/ m2 orally bid on days 1 to 5 ( total dose, 1,000 mg/ m2). This regimen was repeated every 21 days for 6 months. Patients’ median age was 69 years and many had features of advanced disease such as anemia ( 57%), hypoalbuminemia ( 40%), and elevated serum beta(2)-microglobulin ( 43%). Results On an intent-to-treat basis, 83% of patients ( 95% Cl, 73% to 91%) achieved a response, including 7% complete, 67% partial, and 9% minor responses. The median time to response was 4.1 months. The 2-year progression-free survival rate for all patients was 67%; for patients who responded to DRC, it was 80%. The 2-year disease-specific survival rate was 90%. Treatment with DRC was well tolerated, with 9% of patients experiencing grade 3 or 4 neutropenia and approximately 20% of patients experiencing some form of toxicity related to rituximab. Conclusion Our large, multicenter trial showed that the non -stem-cell toxic DRC regimen is an active, well-tolerated treatment for symptomatic patients with WM.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results